OGX-427 in Castration Resistant Prostate Cancer Patients
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study is being offered to patients who have castrate-resistant (also known as
hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the
prostate area to other parts of the body or has recurred in the pelvic area after treatment.
The purpose of this clinical research study is to determine whether OGX-427 is able to slow
the progression of prostate cancer and symptoms of disease when given with prednisone better
than when prednisone is given alone in patients with prostate cancer whose disease has spread
outside the prostate area.
Research Hypothesis:
That adding OGX-427 to prednisone treatment will produce a progression free rate of 20%.